Skip to main content
Clinical Trials/NCT02892786
NCT02892786
Completed
Not Applicable

Detection in Peripheral Blood of Circulating Tumor Cells in Patient With Head and Neck Squamous Cell Carcinoma

Institut de Cancérologie de Lorraine1 site in 1 country40 target enrollmentDecember 8, 2010

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Head and Neck Cancer
Sponsor
Institut de Cancérologie de Lorraine
Enrollment
40
Locations
1
Primary Endpoint
Circulating tumor cells in peripheral blood during head and neck surgery
Status
Completed
Last Updated
7 years ago

Overview

Brief Summary

The dissemination of individual tumor cells is a common phenomenon in solid cancers. Detection of tumor cells in peripheral blood circulating tumor cells (CTC) in nonmetastatic situation is of high prognostic significance.

The objective of our study was to detect circulating tumor cells in two different method in patient with head and neck squamous cell carcinoma .

Registry
clinicaltrials.gov
Start Date
December 8, 2010
End Date
April 2018
Last Updated
7 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Institut de Cancérologie de Lorraine
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Age ≥ 18 years
  • Patient with head and neck squamous cell cancer stage III or IV histologically proven
  • Patient naive to any prior therapy
  • Patient with operate cancer and resectable tumor
  • Hemoglobin ≥ 10g / dL
  • Performance status ≤ 2
  • Ability to provide written informed consent
  • Patient's legal capacity to consent to study participation

Exclusion Criteria

  • Other previous histology tumors
  • Medical conditions or acute or chronic severe psychiatric disorders
  • Deprived of liberty or under supervision

Outcomes

Primary Outcomes

Circulating tumor cells in peripheral blood during head and neck surgery

Time Frame: 7 days

The number of circulating tumor cells detected per milliliter of peripheral blood will be evaluated on the day before, the day of surgery and 7 days after the surgery.

Secondary Outcomes

  • Prognostic marker of relapse(2 years)
  • Comparison between RT-PCR and CellSearch™ method(1 day)

Study Sites (1)

Loading locations...

Similar Trials